Ulcerative Colitis Market Soars to $6.84 Billion in 2023, Registering a 7.7% CAGR - Unlocking Lucrative Investment Opportunities
20 sept. 2023 04h43 HE
|
Research and Markets
Dublin, Sept. 20, 2023 (GLOBE NEWSWIRE) -- The "Ulcerative Colitis Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. The global ulcerative colitis market is...
First Wave BioPharma to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
05 sept. 2023 07h00 HE
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Sept. 05, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
Fecal Calprotectin Test Market revenue to hit USD 350 Million by 2035, says Research Nester
23 août 2023 07h30 HE
|
Research Nester
New York, Aug. 23, 2023 (GLOBE NEWSWIRE) -- The global fecal calprotectin test market size is predicted to grow at a CAGR of over ~12% from 2023 to 2035. The market is projected to garner a revenue...
Fecal Calprotectin Test Market to Grow at 10.7% CAGR, Aiming for USD 355.8 Million by 2031 – TMR Report
24 mai 2023 06h30 HE
|
Transparency Market Research
Wilmington, Delaware, United States, May 24, 2023 (GLOBE NEWSWIRE) -- The global fecal calprotectin test market stood at US$ 126.9 million in 2022 and the global market is projected to reach US$...
Morphic Reports Positive Topline Results of the EMERALD-1 UC Main Cohort; Orally Administered MORF-057 Achieves Primary Endpoint and Demonstrates Clinically Meaningful Improvements Across Secondary and Exploratory Measures
25 avr. 2023 07h00 HE
|
Morphic Therapeutic
-MORF-057 demonstrates statistically significant reduction of 6.4 points (p=0.002) from baseline at Week 12 in the Robarts Histopathology Index (RHI) Score- -MORF-057 achieves 25.7% clinical...
Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2023
25 avr. 2023 06h59 HE
|
Morphic Therapeutic
-In EMERALD-1 Phase 2a trial in patients with ulcerative colitis, MORF-057 meets primary endpoint and demonstrates clinically meaningful improvements across secondary and exploratory measures with no...
Morphic Therapeutic to Host EMERALD-1 Topline Results Call on April 25, 2023
24 avr. 2023 16h01 HE
|
Morphic Therapeutic
WALTHAM, Mass., April 24, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
Expanding Government Assistance is Controlling the Market, Microbiome Therapeutics Market to Grow By 32% CAGR through 2032, Says Fact.MR
08 déc. 2022 09h00 HE
|
FACT.MR
Rockville, Dec. 08, 2022 (GLOBE NEWSWIRE) -- The microbiome therapeutics market size is estimated at US$ 112.20 Bn in 2022 and is anticipated to grow at a CAGR of 32% from 2022 to 2032. The...
Global Inflammatory Bowel Disease Treatment Market Research Report 2022 Featuring AbbVie, Biogen, Johnson & Johnson, Amgen, & UCB SA
08 nov. 2022 06h13 HE
|
Research and Markets
Dublin, Nov. 08, 2022 (GLOBE NEWSWIRE) -- The "Inflammatory Bowel Disease Treatment Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.The global inflammatory...
First Wave BioPharma, Inc. Announces Pricing of $6.0 Million Public Offering
06 oct. 2022 21h00 HE
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Oct. 06, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the...